GSK 1360707
Alternative Names: GSK1360707Latest Information Update: 18 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antidepressants; Anxiolytics; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Depressive disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Anxiety-disorders(In volunteers) in United Kingdom (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Depressive disorders(In volunteers) in United Kingdom (PO)
- 30 Apr 2009 Phase-I clinical trials in Anxiety disorders in United Kingdom (PO)